Ilonze Onyedika J, Knapp Shannon M, Chernyak Yelena, Page Robert L, Boyd LaKeisha J, Mazimba Sula, Raman Subha V, Enyi Chioma O, Allen Larry A, Breathett Khadijah
Division of Cardiovascular Medicine, Indiana University, Indianapolis, IN, United States of America.
Department of Psychiatry, Indiana University, Indianapolis, IN, United States of America.
PLoS One. 2024 Dec 12;19(12):e0310778. doi: 10.1371/journal.pone.0310778. eCollection 2024.
No consensus exists for heart transplant listing for patients who use cannabis. We conducted a web-based survey to assess knowledge, and practice patterns towards patients with heart failure who use cannabis referred for transplant. A total of 140 clinicians (cardiologists (41.4%, n = 58), surgeons (7.1%, n = 10), pharmacists (9.3%, n = 13), advanced practice providers and coordinators) responded and responses were grouped by whether they responded that cannabis is "illegal in my state" (illegal), or "legal for medical and recreational use in my state," (legal). There was a statistically significant difference in responses between the groups in the frequency of cannabis use that should preclude a patient from HT listing p = 0.0330) with respondents where cannabis is legal tending to answer that higher frequencies were acceptable. The groups in the "legal group" responded that a validated cannabis screening questionnaire could evaluate HT eligibility (p = 0.0111). A majority in the illegal group responding "No" as to whether their program allows pre- or post-transplant patients to use prescribed cannabis products (p < 0.0001). A majority in the illegal group responding "No" while the majority in the legal group responded "Yes" to "Does your HT center's current selection criteria policy address medical cannabis use in potential transplant candidates?" (p = 0.0001). Health care providers generally agreed that a validated cannabis use disorder screening questionnaire would be useful and that 6 months of abstinence from cannabis is sufficient prior to HT listing. Significant heterogeneity exists regarding cannabis use as it relates to heart transplantation.
对于使用大麻的患者是否列入心脏移植名单，目前尚无共识。我们开展了一项基于网络的调查，以评估对于转诊进行移植的使用大麻的心力衰竭患者的了解情况和实践模式。共有140名临床医生（心脏病专家（41.4%，n = 58）、外科医生（7.1%，n = 10）、药剂师（9.3%，n = 13）、高级执业提供者和协调员）做出了回应，回应根据他们是否回答大麻在“我所在的州是非法的”（非法），或“在我所在的州用于医疗和娱乐是合法的”（合法）进行分组。两组在应排除患者列入心脏移植名单的大麻使用频率方面的回应存在统计学显著差异（p = 0.0330），大麻合法地区的受访者倾向于回答更高的频率是可以接受的。“合法组”的受访者表示，一份经过验证的大麻筛查问卷可以评估心脏移植资格（p = 0.0111）。非法组中的大多数人对于他们的项目是否允许移植前或移植后患者使用处方大麻产品回答“否”（p < 0.0001）。对于“你们心脏移植中心目前的选择标准政策是否涉及潜在移植候选人使用医用大麻的问题？”，非法组中的大多数人回答“否”，而合法组中的大多数人回答“是”（p = 0.0001）。医疗保健提供者普遍认为，一份经过验证的大麻使用障碍筛查问卷会很有用，并且在列入心脏移植名单之前，6个月不使用大麻就足够了。在与心脏移植相关的大麻使用方面存在显著的异质性。
